Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir

BreastfeedingPediatric

FDA APPROVAL DATE: 07/22/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfuzosin, Carbamazepine, Cisapride, Copanlisib, Dihydroergotamine, Dronedarone, Efavirenz, Ergotamine, Ethinyl estradiol-containing medications, Gemfibrozil, Lovastatin, Lurasidone, Methylergonovine, Midazolam, Midostaurin, Neratinib, Phenobarbital, Phenytoin, Pimozide, Ranolazine, Rifampin, Sildenafil, Simvastatin, St John's Wort, Triazolam

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin

Contra-indicated in patients with moderate to severe hepatic impairment.

Viekira XR is a combined ombitasvir, paritaprevir, ritonavir and dasabuvir extended release tablet.

In May 2018, the FDA announced the discontinuation of Viekira XR with an estimated product availability through until January 1, 2019.

See also separate entries for Ombitasvir/Paritaprevir/Ritonavir (co-packaged with Dasabuvir as Viekira Pak) and Ribavirin.

Our database has 23 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top